Rosalta Indications/Uses

10 mg: As an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Type IIa and IIb).
As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV)
To reduce LDL-C, total-C, and ApoB in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
20 mg: Treatment of hypercholesterolaemia: Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (typ IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.
Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lower treatments (e.g. LDL apheresis) of if such treatments are not appropriate.
Prevention of cardiovascular events: Prevention of major cardiovascular events in patients who are estimated to have risk for a first cardiovascular event (see Pharmacology: Pharmacodynamics under Actions), as an adjunct to correction of other risk factors.